Volpara Health Technologies Limited
VPAHF
Other OTC0.74
USD
+0.20
- -
ISIN
NZVHTE0001S6
Return %
Stock
S&P500
1Y
76.19
18.21
3Y
-26.00
63.29
5Y
-15.91
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Teri Jo Thomas
- Full Time Employees
- 156
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- Simpl House Wellington New Zealand 6011
- IPO Date
- Jan 16, 2018
- Website
- volparahealth.com
- Similar Companies
- Business
- Volpara Health Technologies Limited, a subsidiary of Lunit Inc. since May 2024 and operating under the Lunit brand as of November 2025, develops and markets AI-powered breast imaging analytics software for early breast cancer detection and clinical decision support. The company offers a comprehensive suite of products including Volpara Analytics for optimizing screening operations; Volpara Live for real-time image quality feedback; Volpara Risk and Volpara Risk Pathways for personalized breast, lung, ovarian, and colorectal cancer risk assessment using TC8 models; Volpara Scorecard for density and risk insights; Volpara Patient Hub for customizable reporting and communications; Volpara Science as the underlying AI engine; Volpara Lung for lung screening workflow; and clinical functions such as TruPGMI for positioning assessment, TruPressure for compression optimization, TruRadDose for radiation dose analysis, and Volpara Thumbnail for enhanced patient notifications; all delivered via capital sales, software maintenance agreements, and SaaS models. Founded in 2009 and headquartered in Wellington, New Zealand, with offices in Lynnwood, Washington, USA, the company serves over 3,500 facilities across more than 40 countries including the United States, Australia, New Zealand, United Kingdom, Europe, Asia-Pacific, Middle East, and Africa, impacting nearly 20 million women through de-identified analysis of over 130 million mammography and tomosynthesis images annually. Recent developments include Lunit's completion of its acquisition in May 2024 to integrate Volpara's breast health platform with Lunit's AI diagnostics for a holistic cancer screening ecosystem; the November 2025 rebranding to Lunit International for unified global operations focused on breast health, early detection, and precision oncology; and expansion leveraging Volpara's U.S. presence in over 2,000 sites amid growing AI healthcare demand.
Volpara Health breast density and mammography quality software highlighted in new peer-reviewed research
Volpara Health enters agreement to be acquired by Lunit, Inc.
Volpara Health and LehYup Partner on Cancer Risk Assessment Services at RSNA 2023
Volpara Health ushers in new era of breast imaging at RSNA 2023
Volpara Health partners with Trees that Count to offset carbon emissions